Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate PARIS–(BUSINESS WIRE)– Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing...